Murakami Naoya, Mori Taisuke, Yoshimoto Seiichi, Ito Yoshinori, Kobayashi Kazuma, Ken Harada, Kitaguchi Mayuka, Sekii Shuhei, Takahashi Kana, Yoshio Kotaro, Inaba Koji, Morota Madoka, Sumi Minako, Itami Jun
Department of Radiation Oncology, National Cancer Center Hospital, Tokyo, Japan.
Laryngoscope. 2014 Nov;124(11):E431-6. doi: 10.1002/lary.24839. Epub 2014 Jul 14.
OBJECTIVES/HYPOTHESIS: Treatment of head and neck squamous cell carcinoma (HNSCC) often requires radiotherapy, but relapse can occur. There is, therefore, an urgent need for the identification of a predictive novel biomarker for radiosensitivity. The epithelial cell adhesion molecule (EpCAM) has been shown to promote the transformation of malignant tumors, and EpCAM may have prognostic significance, but it is not known if EpCAM determines prognosis, especially with respect to radiotherapy. Therefore, we determined the incidence of the expression of EpCAM in HNSCC and analyzed the prognostic value in patients with early-stage glottic cancer treated with radiotherapy.
Retrospective analysis.
All patients with HNSCCs examined in our hospital between January 2012 and February 2013 were analyzed prospectively for the expression of EpCAM. T1-2N0 glottic cancer patients who were primarily treated by radiation therapy between 1995 and 2008 were retrospectively investigated. Patients with or without local recurrence after radical radiation therapy were extracted. The relationship between local recurrence and histopathologic EpCAM expression was compared within these two groups.
One hundred eighteen patients with HNSCCs from the nasopharynx, oropharynx, hypopharynx, larynx, oral cavity, paranasal cavity, unknown primary, and other sites were analyzed. Positive expression of EpCAM was noted in the oropharynx, hypopharynx, and larynx (72%, 90%, and 58%, respectively). Seventeen and 22 patients with or without local recurrence were extracted, respectively. There was no difference between two groups, with the exception of EpCAM expression.
The expression of EpCAM in HNSCC was investigated. Patients with strong EpCAM expression were associated with local recurrence after primary radiation therapy.
NA
目的/假设：头颈部鳞状细胞癌（HNSCC）的治疗通常需要放疗，但可能会出现复发。因此，迫切需要鉴定一种预测放射敏感性的新型生物标志物。上皮细胞粘附分子（EpCAM）已被证明可促进恶性肿瘤的转化，并且EpCAM可能具有预后意义，但尚不清楚EpCAM是否决定预后，尤其是在放疗方面。因此，我们确定了EpCAM在HNSCC中的表达发生率，并分析了其在接受放疗的早期声门癌患者中的预后价值。
回顾性分析。
对2012年1月至2013年2月在我院接受检查的所有HNSCC患者进行前瞻性EpCAM表达分析。回顾性调查1995年至2008年间主要接受放射治疗的T1-2N0声门癌患者。提取根治性放疗后有无局部复发的患者。比较这两组患者局部复发与组织病理学EpCAM表达之间的关系。
分析了118例来自鼻咽、口咽、下咽、喉、口腔、鼻腔、原发灶不明及其他部位的HNSCC患者。在口咽、下咽和喉中观察到EpCAM的阳性表达（分别为72%、90%和58%）。分别提取了17例和22例有或无局部复发的患者。除EpCAM表达外，两组之间无差异。
研究了EpCAM在HNSCC中的表达情况。EpCAM表达强的患者与初次放疗后的局部复发相关。
无
